Use of Haemate® P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: A multicentre observational study

Haemophilia

Volumn 19, Issue 2, 2013, Pages 281-286

  Rothschild, C ^a   D'oiron, R ^b   Borel derlon, A ^c   Gruel, Y ^d   Navarro, R ^e   Negrier, C ^f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c CHU CÔTE DE NACRE   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e HÔPITAL SAINT ELOI   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Factor VIII; Haemophilia A; Immune tolerance induction; Inhibitors; Von Willebrand Factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COUGHING; DISEASE SEVERITY; DIZZINESS; DRUG HALF LIFE; ENDOCARDITIS; FEMALE; FOLLOW UP; GASTROENTERITIS; GLOMERULONEPHRITIS; HEAD INJURY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT SAFETY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG COMBINATIONS; FACTOR VIII; FRANCE; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84874111020     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12018     Document Type: Article

References (39)

1. Haya S, Moret A, Cid AR et al. Inhibitors in haemophilia A: current management and open issues. Haemophilia 2007; 13(Suppl. 5): 52-60.
2. Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2: 863-5.
3. Kurth MA, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
4. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn protocol'. Vox Sang 1996; 70(Suppl. 1): 30-5.
5. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
6. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
7. Mauser-Bunschoten EP, Niewenhuis HK, Roosendaal G, van dBH. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
8. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77(Suppl. 1): 31-2.
9. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4: 568-73.
10. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
11. Dimichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 2007; 5(Suppl. 1): 143-50.
12. Lenk H. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres. Vox Sang 1999; 77(Suppl. 1): 28-30.
13. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
14. Kreuz W, Mentzer D, Auerswald G, Becker S, Joseph-Steiner J. Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia 1996; 2(Suppl. 1): 19 (abstract 73).
15. Smith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
16. Rocino A, deBiasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sang 1999; 77(Suppl. 1): 65-9.
17. Coppola A, Di Minno MM, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
18. Coppola A, Arbasi M, Biasoli C, Messina M, Tagliaferri A, Scaraggi F. Immune tolerance induction (ITI) with a FVIII concentrate with high VWF content in inhibitor patients with previous unsuccessful ITI and/or negative predictors of ITI response. Haemophilia 2010; 16(Suppl. 4): 70 (abstract 17P23).
19. Mentzer D, Kreuz W, Auerswald G. Factor VIII antibody elimination after switching from high to intermediate purity Factor VIII concentrate in children with Haemophilia A. 27 Haemophilia Symposium, Hamburg, 1998; Abstract 187.
20. Platokouki H, Pergantou H, Komitopoulou A, Xafaki P. First attempt at immune tolerance induction with factor VIII/von Willebrand factor concentrates in hemophilia A children with high-titre inhibitors. J Coagul Disord 2010; 2: 35-40.
21. Coppola A, Tagliaferri A, Biasoi C et al. Induction (ITI) with a FVIII concentrate at high VWF content in haemophiliacs with previous unsuccessful ITI and/or negative predictors of ITI response. Blood Transfus 2008; 3: S46.
22. Ilonczai P, Schlammadinger A, Oláh Z, Rázso K, Bereczky Z, Boda Z. Successful immune tolerance induction treatment of therapy-resistant acquired haemophilia with high inhibitor titer: a case report. J Thromb Haemost 2007; 5(Suppl. 2): P-T-233.
23. Rivolta GF, DiPerna C, Franchini M et al. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor. Blood Transfus 2010; 8: 66-8.
24. Scaraggi F, Speciale V, Marino R, Scaraggi R. High dose of an intermediate purity factor VIII concentrate for induction of immune tolerance in severe haemophilia A with factor VIII inhibitor. Haemophilia 2006; 12(Suppl. 2): Abstract 14-PO-422.
25. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
26. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl. 1): 33-7.
27. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
28. Kreuz W, Escuriola EC, Auerswald G et al. Immune tolerance induction (ITI) in haemophilia A - patients with inhibitors - the choice of concentrate affecting success. Haematologica 2001; 86(Suppl. 4): 16-22.
29. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-9.
30. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003; 88(Suppl. 9): 9-13.
31. Shima M, Scandella D, Yoshioka A et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
32. Shima M, Nakai H, Scandella D et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 1995; 91: 714-21.
33. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
34. Jacquemin M, Benhida A, Peerlinck K et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000; 95: 156-63.
35. Amano K, Arai M, Koshihara K et al. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Am J Hematol 1995; 49: 310-7.
36. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
37. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S27-31.
38. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
39. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.